Showing 1 - 10 of 5,255
The COVID-19 crisis intensified decade-long debates on the interaction between intellectual property rights (IPRs), competition law and access to affordable life-saving treatments and vaccines. Compulsory licensing of patented medicines is a tried-and-tested method to expand access, particularly...
Persistent link: https://www.econbiz.de/10014541546
Persistent link: https://www.econbiz.de/10013208383
Persistent link: https://www.econbiz.de/10013435474
Persistent link: https://www.econbiz.de/10003365994
international patent applications in the US, Japan, the European Patent Office, and corresponding filings in three developing … undertake detailed analyses of patent prosecution in the three developing countries. Our analyses indicate that measures to … procedural aspects of patent systems, beyond the formal policies targeting secondary applications, that affect outcomes for these …
Persistent link: https://www.econbiz.de/10012964387
Persistent link: https://www.econbiz.de/10011876356
international patent applications in the US, Japan, the European Patent Office, and corresponding filings in three developing … undertake detailed analyses of patent prosecution in the three developing countries. Our analyses indicate that measures to … procedural aspects of patent systems, beyond the formal policies targeting secondary applications, that affect outcomes for these …
Persistent link: https://www.econbiz.de/10012455567
Persistent link: https://www.econbiz.de/10012703028
Over the first half of March 2021, the majority of European governments suspended Astrazeneca's Vaxzevria vaccine as a precaution following media reports of rare blood clots. We analyse the impact of the European Medicines Agency's (EMA) March 18th statement assuring the public of the safety of...
Persistent link: https://www.econbiz.de/10012585624
Over the first half of March 2021, the majority of European governments suspended Astrazeneca's Vaxzevria vaccine as a precaution following media reports of rare blood clots. We analyse the impact of the European Medicines Agency's (EMA) March 18th statement assuring the public of the safety of...
Persistent link: https://www.econbiz.de/10012589862